Deadline Extended in Valeant Offer for ISTA (VRX, ISTA)

Two weeks ago Valeant Pharmaceuticals International, Inc. (NYSE: VRX) made an unsolicited all-cash offer of $6.50/share for ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), a maker of eye-care drugs. The offer valued ISTA at around $327 million, including ISTA’s debt, a premium…

Published January 6, 2012, 11:25am ET · 1 min read

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Two weeks ago Valeant Pharmaceuticals International, Inc. (NYSE: VRX) made an unsolicited all-cash offer of $6.50/share for ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), a maker of eye-care drugs. The offer valued ISTA at around $327 million, including ISTA’s debt, a premium of 68% over ISTA’s most recent closing price.

ISTA has refused Valeant’s offer, calling it “grossly inadequate” but the two companies have been meeting to discuss a deal. Valeant’s original deadline to shareholders has been extended from January 12th to January 31st.

With ISTA shares trading above $7, Valeant is going to have to sweeten the deal if it expects to have a chance of acquiring ISTA.

Contact [email protected] for any questions or corrections.

Paul Ausick

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

All articles →